| |
|
|
|
|
|
|
|||
|
Blood, 19 March 2009, Vol. 113, No. 12, pp. 2746-2754. Prepublished online as a Blood First Edition Paper on January 12, 2009; DOI 10.1182/blood-2008-06-164368.
LYMPHOID NEOPLASIA Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models1 Division of Hematology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA; 2 Dana-Farber Cancer Institute, Boston, MA; 3 Children's Hospital, Boston, MA; 4 Pathology/Dermatology Department and EA2406, Centre Hospitalier Universitaire (CHU) de Bordeaux and Bordeaux 2 University, Bordeaux, France; 5 Department of Pathology, Brigham & Women's Hospital, Boston, MA; 6 Howard Hughes Medical Institute, Boston, MA; and 7 Inserm, E0210, Université Paris Descartes, Hôpital Necker, Paris, France
The tyrosine kinase JAK3 plays a well-established role during normal lymphocyte development and is constitutively phosphorylated in several lymphoid malignancies. However, its contribution to lymphomagenesis remains elusive. In this study, we used the newly identified activating JAK3A572V mutation to elucidate the effect of constitutive JAK3 signaling on murine lymphopoiesis. In a bone marrow transplantation model, JAK3A572V induces an aggressive, fatal, and transplantable lymphoproliferative disorder characterized by the expansion of CD8+TCR
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||